d3 Medicine, a biopharmaceutical strategic advisory company, and Viroclinics Biosciences, a virology service organization, have signed a non-exclusive Memorandum of Understanding to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases.

Viroclinics Biosciences will provide a range of preclinical and clinical diagnostic services, including high throughput serology, virology and molecular assays, phenotyping and genotyping in both translational studies and phase I-IV clinical studies, and clinical trial logistics services. d3 Medicine will formulate integrated development, clinical pharmacology and translational medicine strategies to fast-track preclinical development and define customized pharmacometric and quantitative pharmacological approaches to improve decision making and accelerate clinical and regulatory development.

“Biopharmaceutical companies now can turn to d3 Medicine and Viroclinics Biosciences to develop and implement their preclinical, clinical and regulatory strategies when developing therapeutics, vaccines and diagnostics for viral infectious diseases,” said Dr. Craig Rayner, CEO and co-founder of d3 Medicine.